Mark Munch Sells 2,000 Shares of Bruker (NASDAQ:BRKR) Stock

January 17, 2026 by InsiderTrades.com

Key Points

Insider sale: Bruker VP Mark Munch sold 2,000 shares on Jan. 15 at an average of $49.20 for $98,400 and had earlier sold 7,000 shares on Jan. 12 at $55; his holdings now total 128,443 shares, a ~1.53% reduction.
Company results & outlook: Bruker beat quarterly estimates (EPS $0.45 vs. $0.33; revenue $860.5M vs. $847.4M), set FY2025 guidance of $1.85–$1.90 EPS, and trades around $48.39 with a $7.35B market cap and a consensus analyst rating of Hold (target $53.36).

Bruker Corporation (NASDAQ:BRKR - Get Free Report) VP Mark Munch sold 2,000 shares of Bruker stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $49.20, for a total value of $98,400.00. Following the completion of the sale, the vice president directly owned 128,443 shares in the company, valued at approximately $6,319,395.60. This represents a 1.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Mark Munch also recently made the following trade(s):

On Monday, January 12th, Mark Munch sold 7,000 shares of Bruker stock. The stock was sold at an average price of $55.00, for a total transaction of $385,000.00.

Bruker Trading Down 2.2%

Bruker stock opened at $48.39 on Friday. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.85 and a quick ratio of 0.91. The firm has a 50-day moving average of $47.19 and a 200-day moving average of $40.06. The company has a market cap of $7.35 billion, a price-to-earnings ratio of -302.44, a P/E/G ratio of 6.38 and a beta of 1.17. Bruker Corporation has a one year low of $28.53 and a one year high of $61.01.

Bruker (NASDAQ:BRKR - Get Free Report) last announced its quarterly earnings data on Monday, November 3rd. The medical research company reported $0.45 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.33 by $0.12. Bruker had a positive return on equity of 15.45% and a negative net margin of 0.61%.The company had revenue of $860.50 million for the quarter, compared to analysts' expectations of $847.40 million. During the same quarter in the prior year, the business posted $0.60 EPS. The business's revenue was down .5% compared to the same quarter last year. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. On average, equities analysts expect that Bruker Corporation will post 2.69 earnings per share for the current fiscal year.

Bruker Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 2nd. Shareholders of record on Monday, December 8th were paid a $0.05 dividend. The ex-dividend date was Monday, December 8th. This represents a $0.20 annualized dividend and a yield of 0.4%. Bruker's dividend payout ratio is currently -125.00%.

Institutional Investors Weigh In On Bruker

Institutional investors have recently modified their holdings of the business. Orbis Allan Gray Ltd acquired a new position in shares of Bruker in the second quarter valued at about $192,735,000. AQR Capital Management LLC boosted its holdings in Bruker by 125.3% in the 2nd quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company's stock valued at $137,065,000 after purchasing an additional 1,850,215 shares during the period. Sculptor Capital LP grew its position in shares of Bruker by 18.3% during the 2nd quarter. Sculptor Capital LP now owns 3,074,801 shares of the medical research company's stock worth $126,682,000 after purchasing an additional 476,363 shares in the last quarter. Brown Advisory Inc. increased its holdings in shares of Bruker by 13.9% during the second quarter. Brown Advisory Inc. now owns 2,746,163 shares of the medical research company's stock worth $113,142,000 after purchasing an additional 336,026 shares during the period. Finally, Vaughan Nelson Investment Management L.P. increased its holdings in shares of Bruker by 61.6% during the third quarter. Vaughan Nelson Investment Management L.P. now owns 2,090,155 shares of the medical research company's stock worth $67,909,000 after purchasing an additional 796,510 shares during the period. Institutional investors own 79.52% of the company's stock.

Analyst Ratings Changes

Several research analysts have recently commented on BRKR shares. Barclays lifted their target price on Bruker from $45.00 to $55.00 and gave the stock an "overweight" rating in a research note on Monday, December 15th. UBS Group raised their price target on Bruker from $40.00 to $43.00 and gave the company a "neutral" rating in a report on Tuesday, November 4th. Wolfe Research upgraded shares of Bruker from a "peer perform" rating to an "outperform" rating and set a $60.00 price objective on the stock in a report on Wednesday, December 10th. Wells Fargo & Company increased their price objective on shares of Bruker from $48.00 to $55.00 and gave the company an "overweight" rating in a research report on Monday, December 15th. Finally, The Goldman Sachs Group assumed coverage on shares of Bruker in a research note on Tuesday, December 9th. They set a "sell" rating and a $40.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $53.36.

View Our Latest Research Report on BRKR

About Bruker

(Get Free Report)

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker's product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.